Results 51 to 60 of about 3,923 (195)

Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations [PDF]

open access: yesClinical Infectious Diseases, 2018
Ceftazidime/avibactam and meropenem/vaborbactam are changing the management of invasive infections due to carbapenem-resistant Enterobacteriaceae (CRE), leading to higher rates of clinical cure, decreased mortality, and decreased rates of acute kidney injury compared with colistin-based regimens.
Jason M, Pogue   +2 more
openaire   +2 more sources

QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics

open access: yesFrontiers in Microbiology, 2021
QPX7728 is a novel β-lactamase inhibitor (BLI) that belongs to a class of cyclic boronates. The first member of this class, vaborbactam, is a BLI in the recently approved Vabomere (meropenem-vaborbactam).
Olga Lomovskaya   +8 more
doaj   +1 more source

The Boron–Neuron Connection: The Potential of Boron‐Containing Molecules for Treating Incurable Amyotrophic Lateral Sclerosis

open access: yesChemMedChem, Volume 21, Issue 21, 12 November 2026.
Can a single element help address the multifactorial nature of ALS? Boron‐containing compounds combine responsiveness to reactive oxygen species (ROS), neuroprotective activity, and favorable pharmacological properties, offering a distinctive framework for disease modification in a complex disease like ALS.
Nitesh Sanghai   +5 more
wiley   +1 more source

Structural Basis and Binding Kinetics of Vaborbactam in Class A β-Lactamase Inhibition [PDF]

open access: yesAntimicrobial Agents and Chemotherapy, 2020
Class A β-lactamases are a major cause of β-lactam resistance in Gram-negative bacteria. The recently FDA-approved cyclic boronate vaborbactam is a reversible covalent inhibitor of class A β-lactamases, including CTX-M extended-spectrum β-lactamase and KPC carbapenemase, both frequently observed in the clinic.
Orville A. Pemberton   +4 more
openaire   +2 more sources

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae

open access: yes, 2018
Vaborbactam (formerly RPX7009) is a novel inhibitor of serine β-lactamases, including Ambler class A carbapenemases, such as KPCs. The current study evaluated the in vitro activity of the combination agent meropenem-vaborbactam ...
Michael N. Dudley   +4 more
core   +1 more source

Bocillin™ competition assay probing inhibition of P. aeruginosa PBP3 by vaborbactam.

open access: yes, 2021
SDS PAGE gel fluorescence scan of PBP3 reacted with the fluorescent BocillinTM reporter β-lactam in the presence of varying concentrations of the vaborbactam inhibitor.
Vijay Kumar (377076)   +5 more
core   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 22, Page 6607-6626, November 2026.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Interpretation of Key Updates in the 36th Edition of Clinical and Laboratory Standards Institute M100 Standard

open access: yesiLABMED, Volume 4, Issue 3, Page 133-138, September 2026.
ABSTRACT The Clinical and Laboratory Standards Institute M100 document serves as a cornerstone standard for clinical microbiology laboratories in China. Maintaining the scientific rigor of its predecessors, the 36th edition incorporates updated epidemiological cutoff values, pharmacokinetic/pharmacodynamic data, and clinical efficacy evidence to revise
Kanghong Xu, Qi Wang, Hui Wang
wiley   +1 more source

A Post-Neurosurgical Infection due to KPC-Producing Klebsiella pneumoniae Treated with Meropenem-Vaborbactam: A Case Report

open access: yesInternational Journal of Infectious Diseases, 2022
This case report describes a patient with post-neurosurgical infection and bacteremia caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae.
Seohyun Choi   +4 more
doaj   +1 more source

Successful Rapid Desensitization to Ceftazidime/Avibactam in a Patient With Cystic Fibrosis and Multidrug‐Resistant Pseudomonas aeruginosa Pneumonia: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Ceftazidime/avibactam (CAZ‐AVI) is an important therapeutic option for multidrug‐resistant (MDR) Pseudomonas aeruginosa infections; however, hypersensitivity reactions may preclude its use and create significant therapeutic challenges. We report a 21‐year‐old woman with cystic fibrosis and recurrent MDR P.
Zuoren Zhou   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy